# Delhi HC orders removal of Razenta’s Daplogin trademark 2026-08-21T15:22:59+00:00 | Governance | Indian Opinion Desk Corroboration: 1 independent outlet The Delhi High Court has directed the registrar of trademarks to cancel Indore-based Razenta Pharmaceuticals' trademark 'Daplogin', ruling it is deceptively similar to Dr Reddy's Laboratories' 'Daplo' mark for diabetes drugs. Justice Jyoti Singh held that both products use the same active pharmaceutical ingredient for treating Type-2 diabetes and that the medicines being prescription drugs does not eliminate the likelihood of confusion. The court found Daplogin's registration violates Sections 9(1)(a), 9(2)(a) and 11(1)(b) of the Trade Marks Act, 1999. It noted phonetic similarity can cause confusion at purchase, which must be avoided. Justice Singh also declared Dr Reddy's Daplo a well-known mark under Section 11(6) and Section 2(1)(zg) of the Act, given its investments, revenues, goodwill and popularity. The court ordered the trademark registry to rectify its register within six weeks. It warned that any unauthorised use of an identical or deceptively similar mark by a third party would amount to infringement and passing off, and such registration would be invalid and liable to cancellation. ## Indian Opinion Analysis This ruling reinforces the strict standard Indian courts apply to pharmaceutical trademarks where the drugs treat the same condition and share the same active ingredient. The Trade Marks Act does not exempt prescription medicines from confusion tests, the buyer is often the patient or chemist, not a doctor. Dr Reddy's now has a stronger basis to oppose similar marks in future. The six-week deadline for the registrar to act is typical, but delays in rectification are common. Watch for whether Razenta appeals to a division bench. ## Coverage - legal.economictimes.indiatimes.com Straight court ruling report, no slant detected. This story was synthesised by AI from the source linked above. Tags: Delhi High Court, Dr Reddy's Laboratories, Razenta Pharmaceuticals, Trade Marks Act 1999 Canonical: https://indianopinion.org/delhi-hc-orders-removal-of-razentas-daplogin-trademark/ License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources. Cite: https://indianopinion.org/delhi-hc-orders-removal-of-razentas-daplogin-trademark/#story-in-brief Review state: restored archive article, accurate at time of publication, not offered to search indexes. How this brief was made: an AI model read the report linked above and wrote this summary and analysis, which were published automatically. Published briefs are sampled every hour by an automated quality check; the editor verifies its findings and approves corrections, and corrected briefs carry a dated correction line. We do no original reporting. Methodology: https://indianopinion.org/ai-use-policy/